RUNX1 and acute myeloid leukemia: In the AML1/ETO-positive AML patients carrying wtc-kit [n = 53, about 73% (53/73) of the entire AML1/ETO-positive patients], those expressing high c-kit levels had a shorter OS (14.2%±12.4% at 3 years, median = 20.3 months vs. 81.6%±7.6% at 3 years, median = not reached, P = 0.001) and EFS (10.5%±9.1% at 3 years, median = 9.5 months vs. 58.6%±12.2% at 3 years, median = not reached, P = 0.001) than those expressing low c-kit levels.